Whether methylated-(3")-epigallocatechin gallate is useful for the therapy of NASH(nonalcoholic steatohepatitis)?

在喂食蛋氨酸-胆碱缺乏饮食（MCDD）的非酒精性脂肪性肝炎（NASH）模型小鼠中，甲基化-（3”）-表没食子儿茶素没食子酸酯（Methylated-（3“）-epigallocatechin gallate，MethylEGCG）处理后，肝组织中的炎性细胞浸润、气球样肝细胞、Mallory-Denk小体和细胞周纤维化得到改善。此外，肝细胞中的8-氢-2 '-脱氧鸟苷（8 OhdG）免疫反应产物减少，氧化应激受到抑制。TNFR、pAkt和pNFκB蛋白表达明显降低，pIRS-1蛋白表达明显升高。根据这些结果，MethylEGCG改善了NASH模型小鼠的肝损伤。

After methylated-(3")-epigallocatechin gallate(MethylEGCG) was treated in the nonalcoholic steatohepatitis(NASH) model mice fed a methionine-choline-deficient diet(MCDD), infiltration of inflammatory cells, ballooning hepatocytes, Mallory-Denk body and pericellular fibrosis in the liver tissues improved. In addition, 8-hydro-2'-deoxyguanosine(8OhdG)-immunoreactive products in the hepatocytes were decreased, and the oxidative stress was suppressed. The protein expression of TNFR, pAkt and pNFκB was clearly decreased, and that of pIRS-1 was increased. From these results, MethylEGCG improved the liver injuries in the NASH model mice.